Semax and Selank: What the Research Says About These Cognitive Peptides (2026)

The Peptides Place
Aug 19
5 min read

Updated: 6 days ago

Key Takeaways

Semax and Selank are synthetic peptides developed in Russia decades ago and have been used there in approved clinical formulations, but neither is FDA-approved for any indication in the United States.
Semax's most-documented mechanism is upregulating brain-derived neurotrophic factor (BDNF), a protein tied to neuron growth, survival, and synaptic plasticity; Selank's most-studied mechanism is modulating the GABA system, the brain's primary calming pathway.
The strongest human evidence for either compound comes from small Russian clinical trials in specific patient populations (stroke, generalized anxiety disorder), not from large-scale trials in healthy people seeking cognitive enhancement.
A 2026 evidence review rated Semax's attention and BDNF effects as ‘moderate confidence’ in patient populations, but rated Selank's memory and learning claims as ‘very low confidence’ in humans, since that evidence comes primarily from animal studies.
In July 2026, an FDA advisory committee reviewed Semax for potential U.S. compounding eligibility and flagged bleeding risk, immunogenicity, and impurity concerns as open safety questions; the recommendation is nonbinding and Semax remains unapproved.
Reported side effects for both compounds are generally described as mild in existing literature, but Western, large-scale human safety data remains limited for both.

Two Peptides, Two Different Jobs

Semax and Selank are frequently discussed together because they were developed by the same Russian research group and are often used in combination, but they are not interchangeable. Semax is a synthetic heptapeptide derived from a fragment of ACTH, the body's adrenocorticotropic hormone, and its research profile centers on cognition and neuroprotection. Selank is a synthetic analog of tuftsin, an immune-signaling peptide, and its research profile centers on anxiety reduction and stress resilience. A 2026 clinical overview summarizes the split cleanly: Semax ‘primarily supports cognitive performance,’ while Selank ‘primarily supports emotional regulation.’

How Is Semax Thought to Work?

The most-documented mechanism behind Semax is its effect on brain-derived neurotrophic factor, or BDNF, a protein that supports the survival, growth, and connectivity of neurons. Research summaries describe Semax as working through ‘modulation of the brain's dopaminergic and serotonergic systems’ alongside ‘upregulation of BDNF and its receptor, TrkB,’ a combination researchers believe underlies its reported nootropic and neuroprotective effects. Small clinical studies conducted in Russia have examined Semax nasal spray in stroke patients, children with developmental delay, and cases of optic nerve atrophy, generally reporting improvements in attention, cognitive processing speed, and memory consolidation within those specific patient groups.

It's worth being precise about what that evidence actually supports. A 2026 evidence-grading review looked specifically at claims that Semax ‘improves attention’ and ‘raises BDNF,’ and rated the supporting evidence as coming from ‘small human RCTs’ but only in ‘stroke’ and ‘cognitive impairment’ populations, assigning it ‘moderate confidence’ for those specific patient groups, not for healthy people seeking a general cognitive boost.

How Is Selank Thought to Work?

Selank's research centers on a different neurological system entirely. Its most-studied mechanism is ‘allosteric modulation of the GABAergic system,’ the primary inhibitory network in the central nervous system responsible for producing a calming effect. A second proposed mechanism involves Selank inhibiting enzymes that break down enkephalins, the brain's own opioid-like signaling molecules involved in stress and pain response, which researchers believe may extend their calming activity. Small Russian clinical trials in patients with generalized anxiety disorder have reported anxiolytic, or anxiety-reducing, effects without the sedation typically associated with traditional anti-anxiety medications.

However, the same 2026 evidence review that found moderate support for Semax's cognitive effects in patients was notably more cautious about Selank. It rated Selank's anxiolytic effect in generalized anxiety disorder patients as ‘low confidence,’ and rated its often-cited memory and learning benefits as ‘very low confidence’ in humans specifically, because that evidence currently comes only from animal studies, not human trials.

Are Semax and Selank FDA-Approved in 2026?

Neither Semax nor Selank is FDA-approved for any medical indication in the United States. Semax is also not a scheduled controlled substance, which multiple 2026 sources describe as placing it in ‘a regulatory gray area’ rather than an outright prohibited category, since it ‘cannot legally be marketed or sold as a drug or dietary supplement for human use.’

There has been real regulatory movement in 2026, however. The FDA's April 2026 revised bulk-substance guidance removed Semax from its restricted Category 2 list and scheduled it for review by the Pharmacy Compounding Advisory Committee (PCAC) on July 24, 2026. That committee reviewed Semax alongside several other peptides and, according to FDA briefing materials, raised ‘potential concerns involving bleeding risk, immunogenicity, aggregation, and peptide-related impurities.’ The committee's recommendation is nonbinding, and as of this writing, ‘FDA has not issued a final determination, and Semax is not FDA-approved or listed’ on the federal compounding list. The same FDA review noted at least one adverse-event report involving ocular pain and eye burning after use of over-the-counter Semax nasal drops.

Are Semax and Selank Safe?

Across multiple sources, both compounds are consistently described as ‘generally well tolerated,’ with reported side effects limited mainly to nasal irritation or dryness (more common with nasal-spray delivery), occasional mild headache, and rare dizziness or fatigue. One 2026 clinical comparison summarized both compounds as having a ‘well tolerated’ safety profile with ‘rare reports of mild headache or nasal dryness.’

That said, ‘generally well tolerated in existing reports’ is different from ‘thoroughly studied for long-term safety.’ A 2026 clinical review is direct about this gap for Semax specifically: ‘long-term human safety data for semax is largely absent in Western literature,’ and while ‘some users report mild nasal irritation, stimulant-like effects, or mood changes,’ a comprehensive Western safety record simply does not yet exist. The FDA's own 2026 review echoed this concern at the population level, citing insufficient clinical information to fully characterize the safety profile of Semax across broader intended uses.

The Bottom Line

Semax and Selank have a genuinely longer research history than many peptides currently circulating in wellness communities, including real clinical use in Russia and specific, measurable mechanisms tied to BDNF and GABA signaling, respectively. But that history comes with important caveats: the strongest human evidence involves specific patient populations rather than healthy people seeking cognitive enhancement, Selank's most-cited benefits remain weakly supported in humans, and neither compound is FDA-approved or currently legal for U.S. pharmacy compounding. Anyone considering either peptide should understand that ‘well-tolerated in existing studies’ is not the same as ‘proven safe and effective,’ and should discuss options with a licensed healthcare provider rather than relying on online anecdote.